Q32 Bio was established by experienced drug developers and immunologists aiming to transform the treatment landscape for severe autoimmune and inflammatory disorders. The company advanced its proprietary discovery platforms focusing on adaptive immune modulation and tissue-targeted complement inhibitors. It subsequently transitioned into a publicly traded corporate entity via strategic public market listings under the ticker symbol QTTB, enabling the acquisition of institutional capital to fund multi-phase clinical trials for its lead drug candidates.